Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib Plus Letrozole in Postmenopausal Breast Cancer
NCT02619162Phase 1Completed
- Sponsor
- Spanish National Cancer Research Centre
- Start
- Jul 2015
- Primary completion
- Nov 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nintedanib in breast cancer, sponsored by Spanish National Cancer Research Centre. Primary endpoint: Dose Limiting Toxicity. Started Jul 2015; status: completed.
02
Drugs
nintedanib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02619162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02619162.